Mirum Pharmaceuticals delivers 43% revenue growth, generates free cash flow despite a GAAP loss, and has entered a technical breakout — but two consecutive earnings misses and a historically elevated put/call ratio signal growing market skepticism about near-term execution, creating a binary outcome around the next catalyst.
Thesis pillars
- Consecutive Earnings Misses Concern↑Improving
- Fcf Positive Despite Gaap Loss→Stable
- Fast Revenue Growth Elite Efficiency→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 25, 2026
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $85.81: Concentration risk — Supplier: one specialty pharmacy; Earnings in 5 days (event risk).
Mirum Pharmaceuticals develops and commercializes medicines for rare cholestatic liver diseases, with three FDA-approved products: LIVMARLI (ALGS, PFIC), CHOLBAM (bile acid synthesis disorders), and CTEXLI (CTX, approved February 2025). Revenue comes from U.S. prescription sales... Read more
Sell if holding. Multiple concerning factors at $85.81: Concentration risk — Supplier: one specialty pharmacy; Earnings in 5 days (event risk). Chart setup: No clear chart pattern; technical signals are mixed. Score 6.4/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 5d<=7d. Suitability: speculative.
About Mirum Pharmaceuticals, Inc.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals holds FDA and European Commission approvals for LIVMARLI (maralixibat) for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis, FDA approval for CHOLBAM for bile acid synthesis disorders and peroxisomal disorders, and FDA approval for CTEXLI (chenodiol) for cerebrotendinous xanthomatosis, granted in February 2025. The company targets rare patient populations estimated at roughly 4,000–5,500 ALGS patients and 1,000 PFIC patients in the U.S. and Europe, approximately 1,000–2,000 prevalent CTX patients in the U.S., and an estimated 200–300 prevalent U.S. candidates for CHOLBAM therapy.
Mirum earns revenue through direct specialty sales in the U.S., Canada, and select European countries, with CHOLBAM and CTEXLI distributed through a single specialty pharmacy in the U.S. International markets are covered through license and distribution agreements with rare disease partners. The company acquired the Bile Acid Portfolio from Travere Therapeutics in August 2023 and completed the acquisition of Bluejay Therapeutics in January 2026, adding brelovitug, a Phase 3 monoclonal antibody for hepatitis delta virus infection with FDA Breakthrough Therapy and EMA PRIME designations. Milestone and royalty obligations to Shire (now Takeda) under the Shire License Agreement total up to $109.5 million for Livmarli development milestones, with tiered royalties at low double-digit to mid-teen rates on Shire Licensed Products net sales.
Show full overview
The pipeline binary risk facing Mirum centers on multiple concurrent Phase 2b/3 readouts expected in 2026–2027: volixibat VISTAS topline data in PSC (Q2 2026), AZURE-1 and AZURE-4 Phase 3 topline data for brelovitug (H2 2026), and MRM-3379 Phase 2 BLOOM data in fragile X syndrome (2027). If any registration-enabling trial fails, it could weigh on the company's pipeline NPV materially, as each program targets an indication with no currently approved U.S. therapy. CHOLBAM and CTEXLI distribution depends on a single U.S. specialty pharmacy, concentrating fulfillment risk within a narrow operational channel.
See also: Healthcare · Biotechnology
From Mirum Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Mirum Pharmaceuticals, Inc.
Latest news
- NEWS Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 - Bus — Business Wire neutral
- NEWS MIRM Mirum Pharmaceuticals reports steep Q4 2025 EPS miss, while shares post a small gain in today's trading. - Crowd En — Newser negative
- NEWS Mirum Pharmaceuticals, Inc. (MIRM) expected to beat earnings estimates: What to know ahead of Q1 release - MSN — MSN positive
- NEWS Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $130.00 at Stifel Nicolaus - MarketBeat — MarketBeat positive
- NEWS Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance — Yahoo Finance Singapore positive
Generated 2026-10-29T11:53:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierone specialty pharmacy10-K Item 1: 'We are commercializing Ctexli and Cholbam in the United States through one specialty pharmacy'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $85.81: Concentration risk — Supplier: one specialty pharmacy; Earnings in 5 days (event risk). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $79.80. Score 6.4/10, moderate confidence.
Analyst target: $133.48 (+55.6% upside). Prior stop was $79.80. Stop-loss: $79.80.
Concentration risk — Supplier: one specialty pharmacy; Earnings in 5 days (event risk); Consecutive earnings misses (3).
Mirum Pharmaceuticals, Inc. trades at a P/E of N/A (forward -121.7). TrendMatrix value score: 7.0/10. Verdict: Sell.
20 analysts cover MIRM with a consensus score of 4.3/5. Average price target: $153.
What does Mirum Pharmaceuticals, Inc. do?Mirum Pharmaceuticals develops and commercializes medicines for rare cholestatic liver diseases, with three...
Mirum Pharmaceuticals develops and commercializes medicines for rare cholestatic liver diseases, with three FDA-approved products: LIVMARLI (ALGS, PFIC), CHOLBAM (bile acid synthesis disorders), and CTEXLI (CTX, approved February 2025). Revenue comes from U.S. prescription sales through specialty pharmacies and international partner agreements, with a clinical pipeline including volixibat (PSC/PBC Phase 2b) and brelovitug (HDV Phase 3).